AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Ceryvyn Therapeutics Ltd

0.011

+0.00110.00%

Volume:329.18K

Turnover:3K

Market Cap:15.05M

PE:0.04

High:0.011

Open:0.010

Low:0.010

Close:0.010

52wk High:0.600

52wk Low:0.009

Shares:1.37B

Float Shares:786.04M

Volume Ratio:0.04

T/O Rate:0.04%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.245

EPS(LYR):0.245

ROE:--

ROA:-12.59%

PB:0.51

PE(LYR):0.04

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Ceryvyn Therapeutics Ltd

Exchange:

ASX

Establishment Date:

1984

Employees:

33

Office Location:

117 Camberwell Road,Suite 1, Level 1,Hawthorn East,Victoria,Australia

Website:

http://www.opthea.com

Zip Code:

3123

Phone:

Fax:

- -

Introduction:

Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3, which is in Phase Ib/IIa clinical trials for the treatment of wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited is based in South Yarra, Australia.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/CYV.AU/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CYV.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CYV.AU\",,,,,undefined,":{"symbol":"CYV.AU","market":"AU","secType":"STK","nameCN":"Ceryvyn Therapeutics Ltd","latestPrice":0.011,"timestamp":1789020720000,"preClose":0.01,"halted":0,"volume":329180,"delay":0,"changeRate":0.09999999999999991,"nameEN":"Ceryvyn Therapeutics Ltd","floatShares":786037192,"shares":1367978173,"eps":0.2448,"marketStatus":"Closed","change":0.001,"latestTime":"09-10 16:12:00 AEST","open":0.01,"high":0.011,"low":0.01,"amount":3436,"amplitude":0.1,"askPrice":0.011,"askSize":4684808,"bidPrice":0.01,"bidSize":3295330,"shortable":3,"etf":0,"ttmEps":0.2448,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789084800000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.01,"openAndCloseTimeList":[[1788998400000,1789020000000]],"volumeRatio":0.03539,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CYV.AU","preClose":0.01,"auctionPrice":0.011,"auctionVolume":143982,"auctionTime":1789020601958,"referencePrice":0.011,"referenceTime":1789036203090,"auction":3,"marketStatus":"盘后竞价","timestamp":1789020601958}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CYV.AU\",,,,,undefined,":{"symbol":"CYV.AU","floatShares":786037192,"roa":"-12.59%","roe":"--","lyrEps":0.2448,"volumeRatio":0.03539,"shares":1367978173,"dividePrice":0,"high":0.011,"amplitude":0.1,"preClose":0.01,"low":0.01,"week52Low":0.009,"pbRate":"0.51","psRate":"15047.76","week52High":0.6,"institutionHeld":0,"latestPrice":0.011,"committee":-0.174117,"eps":0.2448,"divideRate":0,"volume":329180,"delay":0,"ttmEps":0.2448,"open":0.01,"prevYearClose":0.6,"prevWeekClose":0.011,"prevMonthClose":0.01,"prevQuarterClose":0.015,"fiveDayClose":0.011,"twentyDayClose":0.012,"sixtyDayClose":0.014,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CYV.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CYV.AU\",market:\"AU\",,,undefined,":[],"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":2482138,"yearFounded":1984,"employeeNum":33,"address":"117 Camberwell Road,Suite 1, Level 1,Hawthorn East,Victoria,Australia","zipCode":"3123","officePhone":"61 3 9826 0399","fiscalYearEnd":"06-30"},"stockCompanyDetail":{"websiteUrl":"http://www.opthea.com","stockEarnings":[{"period":"1week","weight":-0.1667},{"period":"1month","weight":-0.1667},{"period":"3month","weight":-0.2857},{"period":"6month","weight":-0.9833},{"period":"1year","weight":-0.9833},{"period":"ytd","weight":-0.9833}],"compareEarnings":[{"period":"1week","weight":-0.0105},{"period":"1month","weight":-0.0233},{"period":"3month","weight":0.0454},{"period":"6month","weight":0.0554},{"period":"1year","weight":0.096},{"period":"ytd","weight":0.0336}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3, which is in Phase Ib/IIa clinical trials for the treatment of wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited is based in South Yarra, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.085287},{"month":2,"riseRate":0.314286,"avgChangeRate":-0.031514},{"month":3,"riseRate":0.485714,"avgChangeRate":0.034303},{"month":4,"riseRate":0.457143,"avgChangeRate":0.009979},{"month":5,"riseRate":0.2,"avgChangeRate":-0.088423},{"month":6,"riseRate":0.685714,"avgChangeRate":0.070717},{"month":7,"riseRate":0.514286,"avgChangeRate":0.134314},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.016441},{"month":9,"riseRate":0.441176,"avgChangeRate":-0.008232},{"month":10,"riseRate":0.264706,"avgChangeRate":0.008806},{"month":11,"riseRate":0.5,"avgChangeRate":0.010467},{"month":12,"riseRate":0.529412,"avgChangeRate":0.050434}],"exchange":"ASX","name":"Ceryvyn Therapeutics Ltd","nameEN":"Ceryvyn Therapeutics Ltd"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"CYV.AU\",market:\"AU\",,,undefined,":null}}